Your browser doesn't support javascript.
loading
NF-κB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer.
Lalle, Guilhem; Lautraite, Raphaëlle; Bouherrou, Khaled; Plaschka, Maud; Pignata, Aurora; Voisin, Allison; Twardowski, Julie; Perrin-Niquet, Marlène; Stéphan, Pierre; Durget, Sarah; Tonon, Laurie; Ardin, Maude; Degletagne, Cyril; Viari, Alain; Belgarbi Dutron, Laurence; Davoust, Nathalie; Postler, Thomas S; Zhao, Jingyao; Caux, Christophe; Caramel, Julie; Dalle, Stéphane; Cassier, Philippe A; Klein, Ulf; Schmidt-Supprian, Marc; Liblau, Roland; Ghosh, Sankar; Grinberg-Bleyer, Yenkel.
Affiliation
  • Lalle G; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Lautraite R; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Bouherrou K; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Plaschka M; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Pignata A; Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), UMR INSERM 1291, CNRS 5051, Université Toulouse III , Toulouse, France.
  • Voisin A; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Twardowski J; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Perrin-Niquet M; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Stéphan P; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Durget S; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Tonon L; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, Gilles Thomas Bioinformatics Platform, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Ardin M; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, Gilles Thomas Bioinformatics Platform, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Degletagne C; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Viari A; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, Gilles Thomas Bioinformatics Platform, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Belgarbi Dutron L; Biology Department, Ecole Normale Supérieure of Lyon, Lyon, France.
  • Davoust N; Laboratory of Biology and Modelling of the Cell, Ecole Normale Supérieure of Lyon, CNRS UMR 5239, INSERM U1293 , Lyon, France.
  • Postler TS; Department of Microbiology and Immunology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
  • Zhao J; Department of Microbiology and Immunology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
  • Caux C; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Caramel J; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Dalle S; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Cassier PA; Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
  • Klein U; Division of Haematology and Immunology, Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
  • Schmidt-Supprian M; Institute of Experimental Hematology, School of Medicine, Technical University of Munich , Munich, Germany.
  • Liblau R; Center for Translational Cancer Research, School of Medicine, Technical University of Munich , Munich, Germany.
  • Ghosh S; German Cancer Consortium and German Cancer Research Center , Heidelberg, Germany.
  • Grinberg-Bleyer Y; Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), UMR INSERM 1291, CNRS 5051, Université Toulouse III , Toulouse, France.
J Exp Med ; 221(6)2024 Jun 03.
Article in En | MEDLINE | ID: mdl-38563819
ABSTRACT
The outcome of cancer and autoimmunity is often dictated by the effector functions of CD4+ conventional T cells (Tconv). Although activation of the NF-κB signaling pathway has long been implicated in Tconv biology, the cell-autonomous roles of the separate NF-κB transcription-factor subunits are unknown. Here, we dissected the contributions of the canonical NF-κB subunits RelA and c-Rel to Tconv function. RelA, rather than c-Rel, regulated Tconv activation and cytokine production at steady-state and was required for polarization toward the TH17 lineage in vitro. Accordingly, RelA-deficient mice were fully protected against neuroinflammation in a model of multiple sclerosis due to defective transition to a pathogenic TH17 gene-expression program. Conversely, Tconv-restricted ablation of c-Rel impaired their function in the microenvironment of transplanted tumors, resulting in enhanced cancer burden. Moreover, Tconv required c-Rel for the response to PD-1-blockade therapy. Our data reveal distinct roles for canonical NF-κB subunits in different disease contexts, paving the way for subunit-targeted immunotherapies.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis / Neoplasms Limits: Animals Language: En Journal: J Exp Med Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis / Neoplasms Limits: Animals Language: En Journal: J Exp Med Year: 2024 Document type: Article Affiliation country: